Vnitr Lek 2017, 63(3):188-192 | DOI: 10.36290/vnl.2017.039

Type 2 diabetes mellitus and chronic kidney disease

Peter Pon»uch
IV. interná klinika LF UK a UNB, Nemocnica sv. Cyrila a Metoda, Bratislava, Slovenská republika

The number of type 2 diabetic patients is increasing world-wide and a prediction of prevalence of chronic kidney disease up to 2025 in European diabetic population is alarming. Albuminuria and estimated glomerular filtration rate are cardinal biochemical parameters in diagnostics of diabetic nephropathy. Following diagnostic methods are also used: renal ultrasonography, ophthalmoscopy and in not clarified cases renal biopsy. Long-term optimal glycemic control, efficient antihypertensive treatment by angiotensin converting enzyme inhibitor, or angiotensin receptor blocker and recommended protein intake is a cornerstone of therapy. The research is presently focused on new pathophysiological mechanisms, as analysis of genome, microRNA, kidney injury biomarkers and proteomes.

Keywords: chronic kidney disease; type 2 diabetes mellitus

Received: January 30, 2017; Accepted: March 6, 2017; Published: March 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pon»uch P. Type 2 diabetes mellitus and chronic kidney disease. Vnitr Lek. 2017;63(3):188-192. doi: 10.36290/vnl.2017.039.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Martinka E, Pon»uch P, Miąániková M et al. Výskyt diabetickej nefropatie v populácii pacientov s diabetes mellitus na Slovensku: výsledky prieskumu NEFRITI. Forum Diab 2015; 4(3): 198-207.
    2. Kainz A, Hronsky M, Stel VS et al. Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025. Nephrol Dial Transplant 2015; Suppl 4: iv113-iv118. Go to original source... Go to PubMed...
    3. de Boer IH, Rue TC, Cleary PA et al. Long-term renal outcomes of patients with type 1 diabetes and microalbuminuria: an analysis of the DCCT/EDIC cohort. Arch Intern Med 2011; 171(5): 412-420. Go to original source...
    4. Kropelin TF, de Zeeuw D, Holtkamp FA et al. Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor of renal outcome. Nephrol Dial Transplant 2016; 31(9): 1471-1477. Go to original source... Go to PubMed...
    5. Titze S, Schmid M, Köttgen A et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant 2015; 30(3): 441-451. Go to original source... Go to PubMed...
    6. Okąa A, Demeą M, Danią D. Nefropatie u diabetikov v renálnych biopsiách 2000-2015: In: 38. kongres Slovenskej nefrologickej spoločnosti, Bratislava 2016. Zborník abstraktov: 21.
    7. American Diabetes Association. Standards of medical care in diabetes - 2017. Microvascular complications and footcare. Diabetes Care 2017; 40(Suppl 1): S88-S98.
    8. Holman RR, Paul SK, Bethel M et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-1589. Go to original source... Go to PubMed...
    9. Zinman B, Wanner C, Lachin JM et al. for the EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117-2128. Go to original source... Go to PubMed...
    10. Wanner C, Inzucchi SE, Lachin JM et al (for the EMPA-REG OUTCOME investigators). Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4): 323-334. Go to original source... Go to PubMed...
    11. Martinka E, Uličiansky V, Mokáň M et al. Konsenzuálny terapeutický algoritmus pre diabetes mellitus 2. typu. Diabetes a obezita 2016; 16: 9-23.
    12. European Renal Best Practice. Clinical practice guidelines on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR < 45 ml/min). Nephrol Dial Transplant 2015; 30(Suppl 2): ii1-ii46.
    13. Regele F, Jelencsics K, Shiffman D et al. Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes. Nephrol Dial Transplant 2015; 30(Suppl 4): iv26-iv34. Go to original source... Go to PubMed...
    14. Rudnicki M, Beckers A, Neuwirt H et al. RNA expression signatures and posttranscriptional regulation in diabetic nephropathy. Nephrol Dial Transplant 2015; 30(Suppl 4): iv35-iv42. Go to original source... Go to PubMed...
    15. Mischak H, Delles C, Klein J et al. Urinary proteomics based on capillary electrophoresis coupled mass spectrometry in kidney disease: discovery and validation of biomarkers and clinical application. Adv Chronic Kidney Dis 2010; 17(6): 493-506. Go to original source... Go to PubMed...
    16. Linhardt M, Persson F, Currie G et al. Proteomic prediction and renin angiotensin aldosterone system inhibition prevention of early diabetic nephropathy in type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of randomised clinical multicentre trial. BMJ Open 2016; 6(3): e010310. Dostupné z DOI: <http://doi10.1136/bmjopen-2015-010310>. Go to original source... Go to PubMed...
    17. Pena MJ, Mischak H, Heerspink HJL et al. Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. Diabetologia 2016; 59(9): 1819-1831. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.